Accessibility navigation


Riluzole elevates GLT-1 activity and levels in striatal astrocytes

Carbone, M., Duty, S. and Rattray, M. (2012) Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochemistry International, 60 (1). pp. 31-38. ISSN 0197-0186

Full text not archived in this repository.

To link to this article DOI: 10.1016/j.neuint.2011.10.017

Abstract/Summary

Drugs which upregulate astrocyte glutamate transport may be useful neuroprotective compounds by preventing excitotoxicity. We set up a new system to identify potential neuroprotective drugs which act through GLT-1. Primary mouse striatal astrocytes grown in the presence of the growth-factor supplement G5 express high levels of the functional glutamate transporter, GLT-1 (also known as EAAT2) as assessed by Western blotting and (3)H-glutamate uptake assay, and levels decline following growth factor withdrawal. The GLT-1 transcriptional enhancer dexamethasone (0.1 or 1muM) was able to prevent loss of GLT-1 levels and activity following growth factor withdrawal. In contrast, ceftriaxone, a compound previously reported to enhance GLT-1 expression, failed to regulate GLT-1 in this system. The neuroprotective compound riluzole (100muM) upregulated GLT-1 levels and activity, through a mechanism that was not dependent on blockade of voltage-sensitive ion channels, since zonasimide (1mM) did not regulate GLT-1. Finally, CDP-choline (10muM-1mM), a compound which promotes association of GLT-1/EAAT2 with lipid rafts was unable to prevent GLT-1 loss under these conditions. This observation extends the known pharmacological actions of riluzole, and suggests that this compound may exert its neuroprotective effects through an astrocyte-dependent mechanism.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Interdisciplinary centres and themes > Centre for Integrative Neuroscience and Neurodynamics (CINN)
ID Code:25573
Uncontrolled Keywords:EAAT2; Neuroprotection; Citicholine; Parkinson’s disease; Glutamate uptake; Glutamate transporters
Publisher:Elsevier

Centaur Editors: Update this record

Page navigation